Massachusetts Financial Services
IBRX icon

Massachusetts Financial Services’s ImmunityBio IBRX Stock Holding History

Massachusetts Financial Services’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-183,368
Closed -$1.51M – 861
2016
Q1 		$1.51M Buy
183,368
+2,322
+1% +$21.9K ﹤0.01% 711
2015
Q4 		$3.14M Sell
181,046
-1,286
-0.7% -$19.1K ﹤0.01% 689
2015
Q3 		$2.09M Buy
+182,332
New +$3.98M ﹤0.01% 721

Other funds holding IBRX

WCM
Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return
CC
Callan Capital La Jolla, California $1.35B AUM 8.35% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Massachusetts Financial Services's IBRX Position: Q2 2016 in Review

Massachusetts Financial Services sold out of ImmunityBio (IBRX) in Q2 2016, closing a stake of 183,368 shares — an estimated $1.51M sold.

Massachusetts Financial Services first reported a position in IBRX in Q3 2015 and held it in 3 quarters. The position peaked at $3.14M in Q4 2015. 62 funds tracked by Wall St. Rank hold IBRX as of Q2 2016.

  • Massachusetts Financial Services reported no remaining ImmunityBio position as of Q2 2016 after selling out during the quarter.
  • Massachusetts Financial Services sold 183,368 ImmunityBio shares in Q2 2016, an estimated $1.51M.
  • Massachusetts Financial Services first reported a position in ImmunityBio in Q3 2015 and held it in 3 quarters.
  • Massachusetts Financial Services's ImmunityBio position peaked at $3.14M in Q4 2015.
  • 62 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2016.

Based on Massachusetts Financial Services's 13F filing for Q2 2016, filed 12 Aug 2016.